AbbVie's second PhIII hep C study confirms cocktail's promise

AbbVie ($ABBV) is rolling out its second snapshot of promising Phase III data for its hepatitis C cocktail, demonstrating that the vast majority of patients taking the therapy were cleared of the virus after 12 weeks of dosing. Just weeks after the Sapphire I study read out, the second of 6 late-stage trials found that 96% of the treatment-resistant patients in the study responded to the drug. Most of the patients were in the genotype 1a group, considered one of the most difficult to treat in the patient population. The data also helps Enanta ($ENTA), which licensed out ABT-450, one of the three drugs used in the cocktail. As expected, Gilead ($GILD) recently won a breakthrough approval for its pioneering hep C drug sofosbuvir. Now AbbVie and Bristol-Myers Squibb ($BMY) are following close behind with their own competing therapies, which will replace the current standards of care from Merck ($MRK) and Vertex ($VRTX). Release